/
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Recurrent Acute Lymphoblastic Leukemia is an early-stage landscape with 10 programs across 6 companies.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Analysis
67%
Small molecule
6 of 9 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 90% of 10 pipeline programs.
Analysis
2
clinical trials
Clinical Trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)